StockWatch
·
Medical/Dental Instruments
Quarterly ResultMay 7, 2026, 04:43 PM

Nephros Q1 Net Revenue Up 7% to $5.2M; Net Income Down

AI Summary

Nephros, Inc. announced its first quarter 2026 financial results, reporting a 7% increase in net revenue to $5.2 million, with core programmatic revenue growing 23% year over year. Despite top-line growth, net income significantly decreased to $140,000 from $558,000 in the prior year, and Adjusted EBITDA also fell. The decline in profitability was primarily attributed to higher product costs due to U.S. tariffs and a strengthening Euro, along with a revenue mix shift towards lower-margin commercial segment products. Management expressed confidence in long-term growth, citing expansion into new markets and consistent reorder activity.

Key Highlights

  • Net revenue increased 7% to $5.2 million in Q1 2026 from $4.9 million in Q1 2025.
  • Core programmatic revenue grew by 23% year over year.
  • Net income decreased to $140,000 in Q1 2026 from $558,000 in Q1 2025.
  • Adjusted EBITDA was $206,000 in Q1 2026, down from $667,000 in Q1 2025.
  • Gross margin declined to 57% in Q1 2026 from 65% in Q1 2025.
  • Cost of goods sold increased 29% to $2.2 million in Q1 2026.
  • Cash and cash equivalents were $4.0 million as of March 31, 2026, down from $5.4 million at December 31, 2025.
  • Basic net income per common share was $0.01 in Q1 2026, down from $0.05 in Q1 2025.